Loading clinical trials...
Loading clinical trials...
A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation
Conditions
Interventions
cediranib and olaparib
Locations
25
United States
Research Site
Mobile, Alabama, United States
Research Site
Anchorage, Alaska, United States
Research Site
Downey, California, United States
Research Site
Greenbrae, California, United States
Research Site
Orange, California, United States
Research Site
San Diego, California, United States
Start Date
January 17, 2017
Primary Completion Date
August 27, 2019
Completion Date
March 16, 2021
Last Updated
March 8, 2022
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions